+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
27 Aug 2017

STADA Pharma, BioQ Pharma licensing agreement to commercialize 3 ready-to-use infusion products

Specialty pharmaceutical companies, STADA Pharmaceuticals Australia Pty Ltd and BioQ Pharma Incorporated, announced a strategic agreement to commercialize three ready-to-use infusion pharmaceuticals in Australia and New Zealand.

The three-product collaboration between STADA and BioQ includes Ropivacaine ReadyfusOR, an opioid sparing post-surgical pain management therapy, as well as two other product candidates. Ropivacaine ReadyfusOR is a ready-to-use, single use infusion product, which is pre-filled by the manufacturer with 0.2% Ropivacaine. It is a self-contained drug and administration system for delivery at the point of care, activated by a single touch. Ropivacaine ReadyfusOR was recently approved by the Therapeutic Goods Administration.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.